VYNE (VYNE Therapeutics) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYNE VYNE Therapeutics Inc VYNE
38 GF Score
Price $0.87
GF Value $0.58
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

VYNE
38GF Score
VYNE Therapeutics Inc VYNE
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.87 is trading 50.7% above its estimated GF Value™ of $0.58. GuruFocus considers VYNE Therapeutics to be Significantly Overvalued.

Key valuation signals for VYNE:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.58 vs. price of $0.87 (50.7% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
38GF Score

Get the complete analysis for VYNE

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.58
GF Value